Adding icatibant to standard care is safe, improves COVID-19 pneumonia and reduces mortality, proof-of-concept study finds. According to the researchers, a larger phase III study is warranted to determine the clinical value of this treatment.
Spanish researchers evaluated icatibant, a selective antagonist of the bradykinin B2 receptor, as a treatment for hospitalized patients with COVID-19 pneumonia in this randomized, open-label clinical trial. The ICAT·COVID study (NCT04978051) was conducted in Barcelona, in hospitalized patients who required supplemental but not high-flow oxygen or mechanical ventilation. They were assigned 1:1 to treatment with either 30 mg icatibant 3 dd for 3 consecutive days plus standard care or standard care alone, and followed for up to 28 days after initial discharge. The primary and key secondary outcomes were clinical response at day 10 (discharge for at least 48 hours with no adverse events ≥ Grade 3) and clinical effectiveness (no readmission) for 28 days after initial discharge, respectively.
Clinical response occurred in 27 of 37 patients (73.0%) in the icatibant group and 20 of 36 patients (55.6%) in the control group (difference 17.42; 95% CI -4 .22 to 39.06, p = 0.115). Clinical efficacy followed in 37 patients (100.0%) in the icatibant group and in 30 patients (83.3%) in the control group (difference 16.67; 95% CI 4.49-28.84; p = 0.011). No patient died in the icatibant group compared to 6 patients (16.7%) in the control group (p = 0.011). All but 1 patient had side effects and these were evenly distributed across the groups. None of the patients withdrew from the study because of side effects.
Bron:
2023-08-08 11:51:14
#Icatibant #standard #care #COVID19 #pneumonia #MedNet
